Mediterranean Shipping Company S.A. Safbank Line, Ltd. Wilhelmsen Lines A/S (associate member)

Synopsis: The proposed notification deletes any reference to loyalty contracts; reduces the notice requirement for independent action; permits members to enter into individual service contracts, to discuss and exchange service contract information and data, and to adopt voluntary service contract guidelines; and makes other administrative changes as well as restating the agreement. The parties request expedited review.

By Order of the Federal Maritime Commission

Dated: May 6, 1999.

Bryant L. VanBrakle,

Secretary.

[FR Doc. 99–11905 Filed 5–11–99; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as Ocean Freight Forwarder—Ocean Transportation Intermediaries pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. app. 1718 and 46 CFR 515).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, D.C. 20573.

Bittner Shipping, Inc., 6613 Backlick Road, Springfield, VA 22150, Officers: Claudio A. Bittner, President, (Qualifying Individual), Marta A. Bittner, Secretary/Treasurer.

Waldo's Multi-Service, 3462 Golden Gate Way, Lafayette, CA 94549, Renate H. Omania, Sole Proprietor.

Kallista Shipping Corporation, 4345 NW 97th Avenue, Miami, FL 33178, Officers: Israel Garcia, President, Irene Chizmar, (Qualifying Individual).

Stephenson International Shipping, Inc., 16110 Armistead, Odessa, FL 33556, Officer: Robert Stephenson, President, (Qualifying Individual).

Tatsumi Intermodal (U.S.A.), Inc., 19780 Pacific Gateway Drive, Torrance, CA 90502, Officers: Hideki Yoshimura, President, (Qualifying Individual), Kazuhisa Goko, Exec. Vice President.

All Freight Services International, Inc., 8240 N.W. 52nd Terrace, Suite 518, Miami, FL 33166, Officers: Murray Norkin, President, Elizabeth Garcia, Exec. Vice President, (Qualifying Individual).

Fleetwood Shipping Inc., 5990 North Belt East, Suite 601, Humble, TX 77396, Officer: Dennis Jay Summers, President, (Qualifying Individual).

Pan Star Express (Chicaog) Corporation, 228 Howard Street, Des Plaines, IL 60018, Officers: Ivy Wang, Chief Financial Officer, Ken Chen, Secretary.

J.F. Hillebrand USA, Inc., 1600 St. Georges Avenue, Suite 301, Rahway, NJ 07065, Officers: Jean-Jacques Francoulon, President, Dorothee Filbinger-Maier, Vice President, (Qualifying Individual).

Murphy International Corporation d/b/a, Murphy Overseas Corporation, International, Transport & Logistics Corporation, 249 E. Ocean Blvd., Suite 400, Long Beach, CA 90802, Officers: Robert Murphy, President, Drew Reynolds, Vice President, Joseph Velez, (Qualifying Individual).

Four Winds International Group, Inc., 1500 S. W. First Avenue, Suite 850, Portland, OR 87201, Officers: Jerome Rose, President, Kevin M. Griffin, Vice President, (Qualifying Individual).

Mid West Orient (New York) Ltd., 151 Summer Avenue, Kenilworth, NJ 07033, Officer: Mariko Semba, President, (Qualifying Individual).

First Air Express, Inc. d/b/a FAE Transportation, Bison Warehouse and Distributing, 11800 Stonehollow Drive, Suite 200, Austin, TX 78758, Officers: Allen T. Love, President, Lisa D. Counts, Vice President, James C. Savage, (Qualifying Individual).

Dated: May 7, 1999.

Bryant L. VanBrakle,

Secretary.

[FR Doc. 99–11929 Filed 5–11–99; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL MARITIME COMMISSION

[Petition P3–99]

Petition of China Ocean Shipping (Group) Company for a Partial Exemption From the Controlled Carrier Act; Extension of Time

On April 8, 1999, the Commission published notice of the filing of a petition by China Ocean Shipping Company (COSCO) seeking a partial exemption from the controlled carrier provisions of the Shipping Act of 1984, as amended. (64 FR 17181) Replies to the COSCO petition are due on May 7, 1999. Sea-Land Service, Inc. and American President Lines, Ltd., seek a 90-day extension of the comment period. COSCO opposes the requested extension.

Due to the press of other business, there will be some delay before the Commission considers the petition; thus, there appears to be no valid reason to deny a reasonable extension. Accordingly, the date set for replies to this proceeding is extended to July 6, 1999.

Replies shall consist of an original and 15 copies, be directed to the Secretary, Federal Maritime Commission, Washington, D.C. 20573–0001, and be served on counsel for Petitioner, Richard D. Gluck, Esq., Garvey, Schubert & Barer, 1000 Potomac Street, N.W., Washington, D.C. 20007.

Copies of the petition are available for examination at the Washington, D.C. office of the Secretary of the Commission, 800 North Capitol Street, N.W., Room 1046.

Bryant L. VanBrakle,

Secretary.

[FR Doc. 99–11992 Filed 5–11–99; 8:45 am]

BILLING CODE 6730–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 99116]

Cooperative Agreement for Applied Research on New Vaccines; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC), National Immunization Program in cooperation with the Office of Prevention Research, announces the availability of fiscal year (FY) 1999 funds for a cooperative agreement program for Applied Research on New Vaccines. This program addresses the ''Healthy People 2000'' priority area of Immunization and Infectious Diseases. The purpose of the program is to initiate an extramural applied research program focused on new vaccines.

B. Eligible Applicants

Applications may be submitted by public and private non-profit and for profit organizations and by governments and their agencies; that is, universities, colleges, research institutions, hospitals, managed care organizations, other public and private nonprofit and profit organizations, State and local governments or their bona fide agents, and federally recognized Indian tribal governments, Indian tribes, or Indian tribal organizations.

Note: Public Law 104–65 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any other form.

C. Availability of Funds

Approximately $725,000 is available in FY 1999 to fund 2 to 3 awards. It is expected that the average award will range from $225,000 to $350,000 to begin on or about September 30, 1999, and will be made for a 12-month budget period within a project period of up to 3 years. Funding estimates may change.

Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

D. Programmatic Interests

Cooperative agreement applications for research projects that address clinical, epidemiologic, or health services delivery questions about new vaccines are being sought. The focus of the cooperative agreement is to eliminate gaps in the available information about new vaccines or their use which is impeding the fullest application of vaccines and their maximum impact on disease. Such gaps may exist for numerous reasons including the small size of populations studied in pre-licensure trials, or the lack of diversity in the populations studied. Applications which propose research studies whose findings have a high probability of being translated into new recommendations for vaccine use by national advisory bodies or whose findings are likely to lead to decreases in vaccine preventable disease morbidity or mortality are encouraged.

Applications must address a programmatic interest area as noted below. Examples of possible projects are also given below; these examples are not to be considered as an exhaustive list but include projects which NIP views as merely exemplifying the priority areas.

1. Clinical or Epidemiologic Research

a. Clinical or epidemiologic topics about new vaccines (including varicella, rotavirus).

For example, there is programmatic interest in assessing the safety and immunogenicity of varicella vaccine among asthmatic children and determining the best immunization regimen. Also, there is interest in learning more about the safety and immunogenicity of rotavirus vaccine among premature infants.

b. Clinical or epidemiologic topics about existing vaccines that have the potential to be recommended for universal use (including hepatitis A). For example, there is programmatic interest in examining the efficacy of a single dose of hepatitis A vaccine in conferring long lasting protection.

c. Clinical or epidemiologic topics about new vaccines expected to be licensed for universal use (including conjugate pneumococcal, live influenza vaccines). For example, there is interest in assessing correlates of protection for pneumococcal vaccine and determining optimal approaches to preventing pneumococcal infection among high risk groups such as those with sickle cell disease.

d. Clinical or epidemiologic topics about the diseases prevented by new vaccines (including disease burden, impact of vaccination, risk factors for disease). For example, there is interest in defining the impact of pneumococcal vaccine on health care utilization and on diagnostic and management practices for children with high fever or common respiratory infections.

2. Health Services Research

Health services delivery topics about the implementation of new vaccine policies and recommendations.

For example, there is interest in what factors influence providers' implementation of new vaccines, including the insurance coverage, parental out-of-pocket costs, and factors influencing decisions by purchasers of health care, insurers of health care, and managed care organizations about coverage for new vaccines.

E. Program Requirements

In conducting activities to achieve this program, the recipient shall be responsible for the activities listed under 1. Recipient Activities, and CDC shall be responsible for conducting activities listed under 2. CDC Activities.

1. Recipient Activities

(a) Design the study: Determine the approaches to take in addressing the questions of interest in the study and develop a study protocol.

(b) Implement the study protocol: Conduct the study according to the protocol and resolve problems in study implementation as they arise.

(c) Analyze data: Plan the analytic approach to be taken to understand and interpret the principal findings from the study.

(d) Prepare manuscripts and publish results: Prepare written manuscript describing the main study findings for publication in a peer reviewed journal.

2. CDC Activities

(a) Provide technical and programmatic information: CDC scientists will provide current scientific and programmatic information relevant to the project.

(b) Assist in executing the study: CDC scientists may collaborate as appropriate in each phase of the study including design, implementation, analysis, and publication. CDC may provide laboratory support, depending on the project funded and the availability of services.

(c) Assist in the development of a research protocol for Institutional Review Board (IRB) review by all cooperating institutions participating in the research project.

The CDC IRB will review and approve the protocol initially and on at least an annual basis until the research project is completed.

Application Content

Use the information in the Program Priorities, Cooperative Activities, Other Requirements, and Evaluation Criteria sections to develop the application content. Your application will be evaluated on the criteria listed, so it is important to follow them in laying out your program plan.

F. Submission and Deadline

Letter of Intent (LOI)

Your letter of intent should identify the announcement number, the intended submission deadline, name the principal investigator, and specify the study area addressed by the proposed project. The letter of intent must be submitted on or before June 15, 1999, to: Sharron Orum, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Announcement 99116, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146.

Application

Submit the original and five copies of PHS–398 (OMB Number 0925–0001) (adhere to the instructions on the Errata Instruction Sheet for PHS 398) on or before July 15, 1999, to: Sharron Orum, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Announcement 99116, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146.

Deadline: Applications shall be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date; or (b) Sent on or before the deadline date and received in time for submission to the review process. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a

commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late Applications: Applications which do not meet the criteria in (a) or (b) above are considered late applications, will not be considered, and will be returned to the applicant.

G. Evaluation Criteria

Applications that are responsive may be subjected to a preliminary evaluation (triage) by a peer review group to determine if the application is of sufficient technical and scientific merit to warrant further review; the CDC will withdraw from further consideration applications judged to be noncompetitive and promptly notify the principal investigator/program director and the official signing for the applicant organization. Those applications judged to be competitive will be further evaluated by a dual review process. Awards will be made based on priority score and programmatic priorities as determined by a secondary review panel, and the availability of funds.

The first review will be a peer review on all applications. Factors to be considered will include:

1. The specific aims of the research project, i.e. the objectives and the hypothesis to be tested.

2. The background of the proposal, e.g., the basis for the present proposal, a critical evaluation of existing knowledge, and the specific vaccine preventable disease knowledge gaps which the proposal intends to fill.

3. The significance and originality of the proposed research.

4. The progress of preliminary studies, if any, pertinent to the application.

5. The adequacy of the proposed research design, approaches, and methodology to carry out the research, including quality assurance procedures and plans for data management and statistical analyses.

6. The extent to which the research findings are likely to fill important information gaps about new vaccines and lead to new vaccine preventable disease policies and recommendations by advisory groups or feasible, cost-effective interventions.

7. Qualifications, adequacy, and appropriateness of personnel to accomplish the proposed activities.

8. The degree of commitment and cooperation of other interested parties (as evidenced by letters detailing the nature and extent of the involvement).

9. The reasonableness of the proposed budget to the proposed research.

10. Adequacy of existing and proposed facilities and resources.

11. Inclusion of Women and Racial and Ethnic Minorities in Research.

The degree to which the applicant has met the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research. This includes:

A. The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation.

B. The proposed justification when representation is limited or absent.

C. A statement as to whether the design of the study is adequate to measure differences when warranted.

D. A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits

12. Human subjects:

The extent to which the application adequately addresses the requirements of Title 45 CFR part 46 for the protection of human subjects.

The second review will be conducted by a secondary review committee of senior Federal officials. The factors to be considered will include:

1. The results of the peer review.

2. Program balance among the two major areas of interest: (a) The clinical and epidemiologic topics surrounding new vaccines and the diseases they prevent, and (b) the health services delivery and program implementation topics.

3. Budgetary considerations.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of:

1. progress reports semiannual;

2. financial status report, no more than 90 days after the end of the budget period; and

3. final financial status and performance reports, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the ''Where to Obtain Additional Information'' section of this announcement.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I in the application kit.

AR–1 Human Subjects Requirements
AR–2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
AR–9 Paperwork Reduction Act
AR–10 Smoke-Free Workplace Requirements
AR–11 Healthy People 2000
AR–12 Lobbying Restrictions

I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under Sections 301 and 307 of the Public Health Service Act, 42 U.S.C. section 241 and 242*l*. The Catalog of Federal Domestic Assistance Number is 93.185.

J. Where To Obtain Additional Information

This and other CDC announcements may be downloaded from the CDC Internet homepage—http://www.cdc.gov. Click on ''funding.''

To receive additional written information and to request an application kit, call 1–888–GRANTS4 (1–888–472–6874). You will be asked to leave you name and address and will be instructed to identify the Announcement number of interest. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: Sharron Orum, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Announcement 99116, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146, Telephone: (770) 488–2716, E-mail: spo2@cdc.gov

For program technical assistance, contact: Roger Bernier, PhD, MPH, Associate Director for Science, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS–E05, Atlanta, Georgia, 30333, Telephone: (404) 639–8204, E-mail: rhb2@cdc.gov

Dated: May 6, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–11928 Filed 5–11–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Head Start Bureau; Advisory Committee on Head Start Research and Evaluation; Notice of Meeting

AGENCY: Administration for Children, Youth and Families, ACF, DHHS.